Kapoor John R, Heidenreich Paul A
University of Chicago Pritzker School of Medicine, 5841 South Maryland Avenue, Chicago, IL, 60031, USA.
Curr Heart Fail Rep. 2012 Jun;9(2):133-8. doi: 10.1007/s11897-012-0086-8.
Tachycardia has been associated with worse outcomes for patients with heart failure and is also thought to have a direct adverse impact on the myocardium. This report highlights the current evidence for heart rate as both a risk factor and mediator for poor outcome for patients with heart failure. We summarize the large number of studies evaluating heart rate in patients with systolic dysfunction and newer studies that examine patients with preserved systolic function. The effect on outcomes in heart failure of medications known to slow the heart rate such as β-blockers and the more recently developed drug ivabradine are discussed. The data clearly show that a high heart rate is a marker of increased mortality. There is also a strong suggestion that a higher heart rate directly worsens outcome and that this can be mitigated by heart rate-reducing medications.
心动过速与心力衰竭患者的不良预后相关,并且也被认为对心肌有直接的不利影响。本报告强调了目前关于心率作为心力衰竭患者不良预后的危险因素和介导因素的证据。我们总结了大量评估收缩功能障碍患者心率的研究以及最新的针对收缩功能保留患者的研究。讨论了已知能减慢心率的药物(如β受体阻滞剂)以及最近研发的药物伊伐布雷定对心力衰竭患者预后的影响。数据清楚地表明,高心率是死亡率增加的一个标志。也有强有力的证据表明,较高的心率会直接使预后恶化,而这可以通过降低心率的药物来缓解。